At a time when even colossal business deals are often carried out via speakerphones and videoconferencing, Merck & Co.’s $14.2 billion sale of such brand lines as Claritin and Coppertone to Germany’s Bayer AG played out like a throwback to the “Mad Men” era.
“When we were down to the wire, we had 40 people fly in from Germany from Bayer, and Merck brought in 35 from New Jersey and other parts of the Merck empire for face-to-face meetings for a week,” says former Fried, Frank, Harris, Shriver & Jacobson M&A co-head David Shine, who represented Merck. “I’ve done multibillion-dollar deals where no one met face to face.” (Shine lateraled to Paul Hastings in March.)
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
